Event Details
Unknown (Past)
Description
Surgery and tissue acquisition for outlier patient
Participants (2)
| Name | Type | Mentions | |
|---|---|---|---|
| Anonymous Patient | person | 4 | View Entity |
| Solit | person | 8 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_015498.jpg
This document is a page from a Nautilus Education publication (likely a magazine or educational material) marked with a House Oversight Bates stamp. It details scientific research into cancer treatment 'outliers' or exceptional responders, specifically focusing on a patient treated at Memorial Sloan-Kettering by Dr. Solit using the drug everolimus. The text discusses the genetic mutations (TSC1 and NF2) involved and describes a subsequent project launched by the National Cancer Institute, led by Barbara Conley, to identify similar cases in historical clinical trial data.
Related Events
Events with shared participants
Solit's group solved a ureteral cancer mystery involving a RAD50 mutation.
Date unknown • Unknown
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event